5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as 5-ht4 receptor ligands

US6255319A · kind A · utility

Assignee

• Sanofi-Synthelabo · FR

Inventors

• Samir Jegham · Montferrier-sur-Lez, FR
• Alistair Lochead · Moissac, FR
• Frederic Galli · Vaucresson, FR
• Alain Nedelec · Colombes, FR
• Axelle Samson · Paris, FR
• Thierry Gallet · Palaiseau, FR

Key dates

• Filing date: Oct 15, 1999
• Grant date: Jul 3, 2001
• Expiry date: Oct 15, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compound of general formula (I) ##STR1## in which R.sub.1 represents an alkyl or cycloalkylmethyl group, X.sub.1 represents a hydrogen or halogen atom or an alkoxy group, or alternatively OR.sub.1 and X.sub.1 together represent an --OCH.sub.2 O--, --O(CH.sub.2).sub.2 --, --O(CH.sub.2).sub.3 --, --O(CH.sub.2).sub.2 O-- or --(CH.sub.2).sub.3 O-- group, X.sub.2 represents a hydrogen atom or an amino group, X.sub.3 represents a hydrogen or halogen atom, and R.sub.2 represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted phenylalkyl group or a group --(CH.sub.2).sub.n CO--Z in which n represents a number from 1 to 6 and Z represents a 1-piperidyl group. Therapeutic application.